CVAC News and Press, CureVac N.V. From 05/23/23

2023-05-23 14:10:22 ET Despite sharp year-to-date declines, shares of leading COVID-19 vaccine developers spiked on Tuesday amid fears that China is facing a new wave of coronavirus infections. Respiratory disease specialist Zhong Nanshan warned that the country would see as many as 65M...

2023-05-22 17:43:28 ET Summary BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell lung cancer patients that is expected to take place in 2023. Updated results from the expansion cohort from phase 1/2 study using BNT...

2023-05-19 08:41:07 ET CureVac N.V. ( NASDAQ: CVAC ) announced Friday that its motion to transfer the ongoing patent litigation filed by Pfizer ( NYSE: PFE )/BioNTech ( NASDAQ: BNTX ) has been granted, and the decision is likely to "significantly" speed up the progre...

Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the desi...

Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains TÜBINGEN, GERMANY and BOSTON, MA / A...

2023-04-25 15:25:02 ET CureVac N.V. (CVAC) Q4 2022 Earnings Conference Call April 25, 2023 09:00 AM ET Company Participants Alexander Zehnder - CEO Pierre Kemula - CFO Myriam Mendila - Chief Development Officer Sarah Fakih - VP Corporate Communications and IR...

2023-04-25 14:16:04 ET Summary Positive preliminary results were released by CureVac N.V. from both the flu and Covid-19 vaccine programs back in January of 2023. GlaxoSmithKline is an established partner to advance both the Covid-19 and flu prophylactic vaccine programs. The ...

2023-04-25 10:13:33 ET The following slide deck was published by CureVac N.V. in conjunction with their 2022 Q4 earnings call. For further details see: CureVac N.V. 2022 Q4 - Results - Earnings Call Presentation

2023-04-25 07:30:19 ET CureVac BV press release ( NASDAQ: CVAC ): Q4 pre-tax loss was €128.7 million for the three months ended compared to €4.5 million  in the same respective periods of 2021. Revenue of €11.7M (-71.6% Y/Y). Cash and cas...

In 2022, ongoing business transformation driven by COVID-19 and flu clinical develop­ments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac's proprietary mRNA technology platform from positive preliminary Phase 1 data in ...